Genome-wide investigation of maximum habitual alcohol intake (MaxAlc) in 247,755 European and African Ancestry U.S. Veterans informs the relationship between habitual alcohol consumption and alcohol use disorder.

J. D. Deak, Ph.D.[1,2]; D. F. Levey, Ph.D.[1,2]; F. R. Wendt, Ph.D.[1,2]; H. Zhou, Ph.D.[1,2]; M. Galimberti, Ph.D.[1,2]; H. R. Kranzler M.D.[3,4]; J. M. Gaziano M.D.[5,6,7]; M.B. Stein M.D. MPH[8,9;]; R. Polimanti, Ph.D.[1,2]; The Million Veteran Program; J. Gelernter M.D.[1,2].

[1]Yale School of Medicine, New Haven, CT.
[2]VA Connecticut Healthcare Center, West Haven, CT.
[3]University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
[4]Crescenz VA Medical Center, Philadelphia, PA.
[5]Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare System, Boston, MA.
[6]Department of Medicine, Divisions of Aging and Preventative Medicine, Brigham and Women's Hospital, Boston, MA
[7]Department of Medicine, Harvard Medical School, Boston, MA.
[8]University of California, San Diego, La Jolla, CA.
[9]VA San Diego Healthcare System, San Diego, CA.

Correspondence: Address correspondence to Joel Gelernter, Department of Psychiatry, Human Genetics Division, Yale University School of Medicine, New Haven, CT. Electronic mail may be sent to joel.gelernter@yale.edu.

Manuscript Word Count: 2,967

Key Points

Question: What is the genetic etiology of maximum habitual alcohol intake (MaxAlc) and how does it compare to other alcohol consumption measures.

Findings: This MaxAlc study in 247,455 European and African ancestry individuals identified 15 genome-wide significant loci, including multiple novel associations. MaxAlc was strongly genetically correlated (r_g) with measures of alcohol-related problems, demonstrated significantly different r_g with psychiatric traits compared to other alcohol consumption traits, and loaded on a factor with alcohol problem traits while alcohol consumption state measures loaded on a separate factor.

Meaning: MaxAlc is genetically different from trait consumption measures in relation to problematic alcohol use.

Abstract

Importance: Alcohol genome-wide association studies (GWAS) have generally focused on alcohol consumption and alcohol use disorder (AUD); few have examined habitual drinking behaviors like maximum habitual alcohol intake (MaxAlc).

Objective: Identify MaxAlc loci and elucidate the genetic architecture across alcohol traits.

Design: The MaxAlc GWAS was performed in Million Veteran Program (MVP) participants enrolled from January 10, 2011 to September 30, 2020. Ancestry-specific GWAS were conducted in European (EUR) (n=218,623) and African (AFR) (n=29,132) ancestry subjects, then meta-analyzed (N=247,755). Linkage-disequilibrium score regression (LDSC) was used to estimate SNP-heritability and genetic correlations (r_g) with other alcohol and psychiatric traits. Genomic structural equation modeling (gSEM) was used to evaluate genetic relationships between MaxAlc and other alcohol traits. Mendelian randomization (MR) was used to examine causal relationships. MTAG (multi-trait analysis of GWAS) was used to analyze MaxAlc and problematic alcohol use (PAU) jointly.

Setting: The study was performed in a sample of U.S military Veterans.

Participants: Participants were 92.68% male and had mean age=65.92 (*SD*=11.70). 36.92% reported MaxAlc ≥ the binge-drinking threshold.

Main Outcomes(s) and Measure(s): MaxAlc was defined from survey item: "in a typical month, what is/was the largest number of drinks of alcohol you may have had in one day?" with ordinal responses from 0 ≥ 15 drinks.

Results: The MaxAlc GWAS resulted in 15 genome-wide significant (GWS) loci. Top associations in EUR and AFR were with known functional variants *ADH1B**rs1229984 (p=3.12x10^{-104}) and rs2066702 (p=6.30x10^{-17}), respectively. Multiple novel associations were found. The SNP-heritability was 6.65% (s.e.=0.41%) in EUR and 3.42% (s.e.=1.46%) in AFR. MaxAlc was positively correlated with PAU (r_g=0.79; p=3.95x10^{-149}) and AUD (r_g=0.76; p=1.26x10^{-127}), and had negative r_g with "alcohol usually taken with meals" (r_g=-0.53; p=1.40x10^{-50}). For psychiatric traits, MaxAlc had the strongest r_g with suicide attempt (r_g=0.40; p=3.02x10^{-21}). gSEM supported a two-factor model with MaxAlc loading on a factor with PAU and AUD, and other alcohol consumption measures loading a separate factor. MR supported a small causal effect of MaxAlc on the liver enzyme gamma-glutamyltransferase (β=0.012; p=2.66x10^{-10}). MaxAlc MTAG resulted in 31 GWS loci.

Conclusions and Relevance: MaxAlc closely aligns genetically with the etiology of problematic alcohol use traits.

Introduction

Progress has been made in understanding the genetic etiology of many alcohol-related traits(1-2) including alcohol use disorder (AUD)(3-4), forms of problematic alcohol use (PAU)(4-5), and measures of alcohol consumption(3,5-6). A major contribution that genome-wide association studies (GWAS) have made to understanding the genetics of alcohol traits is the finding that the genetic architecture of AUD differs from alcohol use measures(2). Genetic correlation analyses have overturned the idea that alcohol use traits differ from AUD only in degree of use by showing consistently that they differ in nature too(3-5). Quantity-frequency measures like the AUDIT-C (Alcohol Use Disorders Identification Test–Consumption score) correlate genetically with positive metabolic outcomes but not psychiatric disorders, while AUD correlates genetically with psychiatric disorders(3-4). Although these findings have been replicated, they are not well understood and warrant further study(7). Few well-powered efforts have examined the genetic influences across levels of habitual alcohol consumption—an important area of investigation given that higher levels of alcohol intake often lead to increased negative alcohol outcomes.

We aim to improve understanding of the genetic etiology of habitual alcohol consumption by greatly increasing the sample size of GWAS of maximum habitual alcohol intake (MaxAlc)(8) in European (EUR) and African (AFR) ancestry participants in the Million Veteran Program (MVP), and examining the similarities and differences between MaxAlc and other alcohol traits. MaxAlc can be distinguished from similar phenotypes that measure the maximum number of drinks consumed in a lifetime drinking episode ("lifetime max-drinks"), in that MaxAlc captures habitual maximum alcohol intake (i.e., "in a typical month"), while "lifetime max-drinks" may capture consumption on only a single occasion, often being

influenced by "milestone" drinking events (e.g., 21st birthday celebrations)(9). Thus, because MaxAlc is more representative of routine behaviors, it is likely more clinically meaningful and representative of behavior that could result in more negative alcohol-related outcomes than occasional binge-drinking or lower levels of alcohol consumption(10).

The current study is the largest GWAS of MaxAlc to date. The larger sample enables us to estimate the heritability of MaxAlc and examine its genetic correlations with traits from large studies of alcohol consumption and alcohol-related problems. We used genomic structural equation modeling (gSEM) to evaluate the overarching genetic relations between MaxAlc and other alcohol traits. To investigate the impact of MaxAlc on long-term alcohol-related disease, we conducted Mendelian randomization (MR) to examine causal relationships between MaxAlc and liver enzyme levels. Together, these analyses provide a better understanding of the genetic basis of regular heavy drinking and how it compares to the genetics of other alcohol consumption measures and AUD.

Method

Participants and Phenotyping

MVP participants of EUR and AFR ancestry with MaxAlc phenotypic and genotypic data (EUR: n=218,623; AFR: n=29,132) were included resulting in a total sample of 247,755 subjects. MaxAlc was defined using information from the MVP Lifestyle Survey item: "in a typical month, what is/was the largest number of drinks of alcohol you may have had in one day?" with ordinal response options ranging from 0 to ≥ 15 drinks (**Supplemental Figure1**). We removed ≥ second-degree relatives pairwise based on a kinship coefficient >0.0884, prioritizing the retention of the individual with the higher reported MaxAlc value (the heavier drinking

member of the pair of related individuals). The total sample was 92.68% male, had a mean age of 65.92 (SD=11.70), and had 36.92% who reported MaxAlc $\geq$ the binge-drinking threshold(11) (females: $\geq$4 drinks; males $\geq$5 drinks)(**Supplemental Table1**; **Supplemental Figure2**). The study was approved by the Central VA institutional review board (IRB) and site-specific IRBs, including Yale University School of Medicine and VA Connecticut, and was conducted in accordance with all relevant ethical regulations.

Genotyping, Imputation, and Quality Control

Genotyping and imputation for MVP are described in **supplemental materials**.

Ancestry-specific GWAS and Cross-ancestry GWAS meta-analysis

Individual GWAS were conducted on the ordinal trait in the respective MVP samples of EUR and AFR ancestry subjects using a linear regression model implemented in PLINK 2.0(12). Age, sex, and the first 10 within-ancestry genetic PCs were included as covariates. Ancestry-specific GWAS were then meta-analyzed across ancestries using inverse-variance weighting in METAL(13). 1KG Phase 3(14) was used as a reference panel to determine EUR and AFR linkage disequilibrium (LD) structure. Independent GWAS loci were identified using a linkage-disequilibrium (LD) threshold of r^2=0.1 to determine lead SNPs at each genome-wide significant (GWS) locus(15). Variants were assigned to the nearest gene based upon physical position (<10 kb from the assigned gene). Additional gene-mapping techniques using eQTL (expression quantitative trait locus) and 3D chromatin interactions [Hi-C]) data are described in **supplemental materials** (**Supplement Figures18-19**).

Gene, Gene-set, and Tissue-Specific Gene Expression Analysis

Gene, gene-set, and gene expression analyses are described in **supplemental materials**.

SNP-heritability and genetic correlations

LD score regression (LDSC)(16) was used to estimate SNP-heritability (h^2_{SNP}) and to characterize genetic correlations (r_g) with a set of alcohol, psychiatric, and medical traits. Genetic correlations were examined for MaxAlc with alcohol use disorder (AUD)(3), problematic alcohol use (PAU)(4), drinks per week (DPW)(6), a UK Biobank (UKB) measure of "when you drink alcohol is it usually with meals?" (UKB Field ID 1618), and the Alcohol Use Disorders Identification Test (AUDIT) total (AUDIT-T), problems (AUDIT-P), and consumption (AUDIT-C) scales(3,5) in EUR. Measures of AUDIT-C from two samples that have demonstrated differences in substance use problems and demographic composition, MVP and UKB, were included to examine distinctions between the measure across these populations. COV-LDSC(17) was used to estimate MaxAlc h^2_{SNP} in AFR.

Large-scale GWAS of AUD and PAU, unlike alcohol consumption measures, have shown positive genetic correlations with psychiatric disorders(3-4). GWAS have not yet been employed to examine patterns of genetic correlation between psychopathology and heavier alcohol consumption (e.g., MaxAlc) in comparison to AUD and other consumption measures. Thus, we performed genetic correlation analyses between the included alcohol traits and GWAS of anxiety(18), depression(19), PTSD(20), schizophrenia(21), and suicide attempt(22).

Genomic Structural Equation Modeling of alcohol traits

Genomic-SEM (gSEM)(23) was used to evaluate the shared polygenic architecture of MaxAlc, alcohol use problems, and other alcohol consumption measures using GWAS summary statistics. Exploratory factor analysis (EFA) was used to evaluate one-, two-, and three-factor model fit. Confirmatory factor analysis (CFA) was then performed to evaluate model

convergence and factor loadings using conventional model fit indices(23). CFA models were estimated using diagonally weighted least squares estimation and a smoothed genetic covariance matrix to guard against non-positive definite scenarios. The 1kGP Phase 3 EUR reference panel was used to calculate LD(14).

Mendelian Randomization (MR) Analyses

We used Mendelian randomization (MR) to examine causal relationships between MaxAlc and alcohol-related liver enzyme levels with available GWAS data (ALP [alkaline phosphatase], ALT [alanine transaminase], and GGT [gamma-glutamyl transferase])(24) using inverse-variance weighted (IVW), weighted median, and MR-Egger methods in TwoSampleMR(25) and MR-PRESSO(26). MR analysis was limited to liver enzymes demonstrating a significant genetic correlation with MaxAlc. To ensure sufficient genetic instruments to test for causal relationships, we included LD-independent MaxAlc loci reaching a suggestive significance threshold of $p<5.0 \times 10^{-5}$ (nSNPs=171). Multiple methods were used to evaluate method-specific biases to determine consistent effect estimates. Sensitivity analyses, leave-one-out analyses, and outlier removal were all evaluated. The MR-Egger intercept test was used to evaluate the presence of horizontal pleiotropy. MR-PRESSO(26) was used to identify genetic instrument outliers that show horizontal pleiotropy for removal. MR-RAPS (MR-Robust Adjusted Profile Score)(27) was used to test for biased effect estimates due to the inclusion of "suggestive significance" SNPs as genetic instruments.

Multi-trait analysis of MaxAlc and PAU

A joint analysis of EUR MaxAlc and PAU(4) GWAS summary statistics was performed in MTAG (Multi-trait analysis of GWAS)(28). The MTAG analysis is described in **supplemental materials**.

Results

Ancestry-specific GWAS and Cross-ancestry GWAS meta-analysis

The MaxAlc GWAS resulted in 15 LD-independent GWS ($p \leq 5.0 \times 10^{-08}$) loci across the respective analyses (**Figure1**; **Table1**). There were 10 GWS loci in the EUR analysis, 2 GWS loci in the AFR-specific analysis, and 3 additional GWS loci in the cross-ancestry meta-analysis that did not reach GWS in the ancestry-specific analyses.

The top association in EUR was with the well-replicated functional *ADH1B* rs1229984 variant ($p=3.12 \times 10^{-101}$). Additional top GWS loci in EUR included *SLC39A8* (rs13107325; $p=6.78 \times 10^{-15}$), *CRHR1* (rs77804065; $p=6.04 \times 10^{-14}$), *AGBL2* (rs7107356; $p=1.43 \times 10^{-10}$), and *GCKR* (rs1260326; $p=4.53 \times 10^{-08}$). All loci in EUR remained GWS in the cross-ancestry meta-analysis, although there were differences in the lead SNPs identified in the two analyses (**Figure1; Table1**).

The top association in AFR was with the known AFR-specific functional locus at *ADH1B* (rs2066702; $p=6.30 \times 10^{-17}$). A second GWS association was found on chromosome 9 nearest *B4GALT1* (rs56175925; $p=1.83 \times 10^{-08}$)(**Figure1; Table1**).

In the cross-ancestry meta-analysis, three loci not identified in the ancestry-specific GWAS were GWS: rs826323, which maps to *ZNF420* ($p=1.39 \times 10^{-08}$) on chromosome 19; rs6752675 on chromosome 2 nearest *AC092568.1* ($p=2.57 \times 10^{-08}$); and *DRD2**rs2514218 on chromosome 11 ($p=4.59 \times 10^{-08}$)(**Figure1; Table1**).

Gene, Gene-set, and Tissue-Specific Gene Expression Analysis

Gene, gene-set, and gene expression results are reported in **supplemental materials.**

SNP-heritability and genetic correlations

LDSC estimated an observed-scale MaxAlc h^2_{SNP} of 6.65% (s.e.=0.41%) in EUR. LDSC estimates indicated that genome-wide inflation (λ_{GC}=1.26) was likely indicative of the polygenic architecture of MaxAlc as supported by an LDSC intercept=0.99 (s.e.=0.004) and attenuation ratio <0. For AFR, COV-LDSC estimated h^2_{SNP}=3.42% (s.e.=1.46%), a λ_{GC}=1.03, LDSC intercept=0.99 (s.e.=0.007), and attenuation ratio <0.

In EUR, LDSC estimated a high r_g for MaxAlc with PAU (r_g=0.79; p=3.95x10^{-149}) and AUD (r_g=0.76; p=1.26x10^{-127}), a lower r_g with consumption traits (MVP AUDIT-C [r_g=0.35; p=8.49x10^{-15}]; DPW [r_g=0.64; p=1.26x10^{-103}]), and a negative r_g with "alcohol usually taken with meals" (r_g = -0.53; p=1.57x10^{-52})(**Figure2**). Among the psychiatric traits examined, MaxAlc had the highest r_g with suicide attempt (r_g=0.40; p=3.02x10^{-21})(**Figure2; Supplemental Table14**). The MaxAlc r_g with suicide attempt was significantly higher than the r_g between suicide attempt and all other consumption measures, but was not significantly different than the r_g between suicide attempt and AUD or PAU (**Supplemental Table14**). MaxAlc's r_g with depression (r_g=0.23; p=8.40x10^{-16}), PTSD (r_g=0.19; p=4.75x10^{-05}), and anxiety (r_g=0.15; p=5.60x10^{-03}) were also significantly different from those observed for alcohol consumption traits. No significant differences between MaxAlc and other consumption measures were observed for schizophrenia. All alcohol trait correlations with the core psychiatric traits included in the current study are reported (**Supplemental Table14**).

Genomic Structural Equation Modeling

EFA and CFA were conducted using gSEM for MaxAlc and a range of previously-published alcohol traits ranging from AUD to alcohol consumption (AUDIT-C and DPW).

Using EFA to examine different models showed that a common factor model did not adequately capture the relationship across all alcohol traits (cumulative variance explained=0.59)(**Supplemental Table13**). The cumulative variance explained by the two-factor model was 0.82 (Factor 1=0.42; Factor 2=0.40), with high sum of squared (SS) loadings for both Factor 1 (Factor 1 SS=2.91) and Factor 2 (Factor 2 SS=2.83). The three-factor model explained less variance than the two-factor model (cumulative variance=0.80; Factor1=0.35, Factor 2=0.32, Factor 3=0.14) and had SS loadings of 2.42 (Factor 1), 2.23 (Factor 2), and 0.98 (Factor 3). Based on these findings, Factor 3 was not worth retaining given that the three-factor model accounted for less variance and the SS loading of Factor 3 was < 1.0. The two-factor model best fit the data and was evaluated further using CFA.

CFA converged on a two-factor model (correlation=0.67) and demonstrated strong fit across the included alcohol traits (CFI [Comparative Fit Index]=0.98; $\chi 2$= 238.38; AIC [Aikake Information Criterion]=270.38; SRMR [Standardized Root Mean Square Residual]=0.05) (**Figure3; Supplemental Table14**). MaxAlc loaded most strongly on Factor 1 (loading=0.85±0.05) along with PAU (loading=0.93±0.03) and AUD (loading=1.00±0.03). MVP AUDIT-C (loading=0.72±0.04), UKB AUDIT-C (loading=0.84±0.03), DPW (loading=1.02±0.03), and AUDIT-P (loading=0.46±0.06) loaded most strongly on Factor 2, though AUDIT-P also loaded equally well on Factor 1 (loading=0.46±0.05).

Mendelian Randomization (MR)Analyses

Of the three liver enzyme levels examined (ALP, ALT, and GGT), only GGT was significantly genetically correlated with MaxAlc (r_g=0.18; s.e.=0.03; p=1.17x10^{-07}) (**Supplemental Table15**). We thus focused MR analyses on the relationship between MaxAlc and GGT. Following the removal of 13 genetic variant outliers identified by MR-PRESSO, IVW methods indicated a small, but statistically significant causal relationship between MaxAlc and GGT liver levels (beta=0.012; s.e.=0.002; p=2.66x10^{-10})(**Supplemental Table16**). MR-RAPs results indicated that the effect estimates were not biased by the inclusion of SNPs of suggestive significance (**Supplemental Table17**). Even after accounting for all SNP outliers, unexplained heterogeneity remained, potentially due to demographic differences between the two datasets used for the MR analysis (**Supplemental Table16**).

Multi-trait analysis of MaxAlc and PAU

The MaxAlc MTAG analysis provided an increase in EUR MaxAlc equivalent sample size from N=218,623 (GWAS mean $\square$2=1.29) to an equivalent sample size of N=353,981 (MTAG mean $\square$2=1.47), resulting in 31 independent GWS MaxAlc risk loci. The top association was with *ADH1B**rs1229984 (p=3.35x10^{-176}) (**Supplemental Figure16; Table1**). Results for the MTAG analysis of PAU also showed increased locus discovery and are reported in **supplemental materials**.

Discussion

These findings highlight the additional information that can be gleaned from GWAS of habitual alcohol consumption traits that augment prior conclusions from GWAS of other alcohol consumption measures. We identify GWS associations with both novel and well-replicated

alcohol use loci (**Table2**) of etiological relevance for heavy alcohol use, demonstrate distinctive differences in the genetic architecture of AUD and MaxAlc from that of other alcohol consumption traits, and provide insight into the genetic etiology of MaxAlc and its relationship to other psychiatric and medical conditions.

The strongest MaxAlc associations were with the two functional *ADH1B* loci—rs1229984 ($p=3.12 \times 10^{-101}$) in EUR and rs2066702 ($p=6.30 \times 10^{-17}$) in AFR. These *ADH1B* loci, among the few that survived from the candidate gene era(1,30-31), were also identified as risk loci for alcohol dependence in the respective ancestry groups in a GWS context(29). *ADH1B* has been associated with many alcohol traits studied using GWAS, including our previous MaxAlc study(8).

MaxAlc loci at *ADH1B, CRHR1* (rs77804065; $p=6.04 \times 10^{-14}$)*,* and *RP11-655H13.2* (rs1577857; $p=2.47 \times 10^{-08}$) previously identified in EUR or AFR were confirmed in the present study, but the locus at *XPO7* (rs7821592; $p=3.63 \times 10^{-08}$), previously identified for MaxAlc in EUR(8), fell below GWS ($p=1.21 \times 10^{-06}$); although *XPO7* was GWS in the MaxAlc MTAG analysis (**Table1**). Additional GWS associations included loci previously associated with alcohol consumption (3,5-6), PAU(4), and AUD(3) in *SLC39A8* (rs13107325; $p=6.78 \times 10^{-15}$), *GCKR* (rs1260326; $p=4.53 \times 10^{-08}$), and *DRD2* (rs2514218; $p=4.59 \times 10^{-08}$). A summary of GWS associations from the MaxAlc GWAS, including previous associations with other alcohol traits and etiologically relevant outcomes is presented (**Table2**).

We also identified novel associations. For example, the MaxAlc EUR GWAS identified a GWS association (rs7107356; $p=1.43 \times 10^{-10}$) near *AGBL2* (AGBL Carboxypeptidase 2) on chromosome 11. *AGBL2* was previously identified as a risk locus for bitter alcoholic beverage

taste preference(32). Bitter taste preference influences alcohol consumption(33), and genetic influences for bitter taste preference may influence alcoholic beverage intake(34).

A novel finding in the MaxAlc GWAS for AFR was the GWS association near *B4GALT1* (BETA-1,4, Galactrotransferase 1) on chromosome 9. *B4GALT1* is a member of the galactosyltransferase gene family and encodes an enzyme related to both glycoconjugate and lactose biosynthesis(35). Glycoconjugate metabolism occurring in the liver is often altered in the presence of chronic alcohol use, and glycoconjugate-related biomarkers are often considered markers of excessive alcohol use (differentiating alcohol-related vs non-alcohol-related tissue damage)(36). These findings show how MaxAlc GWAS can provide novel insight into the biology of alcohol use, including in non-EUR populations.

LDSC and gSEM results provide insight into differences and similarities in genetic architecture across a broad spectrum of alcohol consumption measures and AUD. Based on genetic correlations, MaxAlc is genetically more similar to AUD and PAU than to measures of alcohol consumption, and is distinct from less problematic drinking styles such as the UK Biobank measure of "having alcohol with meals." MaxAlc, similar to AUD and PAU, demonstrated significant differences in genetic correlation with many psychiatric outcomes compared to the largely negative, or near zero, genetic correlations between psychopathology and other alcohol consumption measures. The strongest genetic correlation between MaxAlc and psychiatric traits was with suicide attempt, which is consistent with the positive phenotypic association between heavy alcohol consumption and suicide behaviors(37).

Our gSEM showed that a two-factor solution best fit the data, including one factor that we suggest captures "alcohol use problems" and a second factor that captures "non-dependent alcohol consumption." MaxAlc loaded most strongly on the "alcohol use problems" factor along

with AUD, PAU, and AUDIT-P (which loaded equally on both factors). Thus, MaxAlc, a measure of habitual alcohol consumption, aligns with traits that capture alcohol use problems rather than episode-limited measures of quantity or frequency of alcohol use. The genetic relationship between alcohol consumption and AUD thus appears dependent upon the steadiness and heaviness of alcohol consumption, which in turn appears to reflect dependent use.

The genetic study of MaxAlc is also positioned to study the impact of habitual alcohol use on alcohol-related disease, such as liver function. Understanding the causal role of problematic alcohol use on alcohol-related medical conditions is important. Previous studies have primarily been limited to examining the relationship between AUD diagnosis and disease(38) although we know that harmful levels of drinking can negatively impact health outcomes even if not meeting AUD diagnostic criteria(39). The MR findings from the current study supported significant genetic overlap and a small causal role of habitual drinking on GGT levels. Clinically, GGT elevations can be pronounced in individuals with a history of heavy drinking, individuals with alcohol-related cirrhosis, and can be valuable for detecting alcohol-induced liver disease(40). Genetically-informed studies of MaxAlc can help understand the biological and medical consequences of habitual drinking.

The current study has limitations. The MVP is a predominately male U.S. military Veteran sample and the results reflect this demographic. Additionally, retrospective reports such as MaxAlc may be subject to longitudinal changes and reporting bias(41). MaxAlc also has sample size restrictions for non-European subjects as is currently true for many genetic studies of complex traits.

The present study is valuable in understanding etiologically-relevant mechanisms involved as normative alcohol consumption approaches habitual problematic use, and ultimately,

AUD(42). These efforts provide promise for the continued advancement of our understanding of

the etiology across the spectrum of alcohol consumption levels and AUD, and how these levels

of alcohol use relate to other psychiatric and health conditions.

Funding: This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration, and was supported by MVP and the Veterans Affairs Cooperative Studies Program study No. 575B. This work was supported by NIH grants R01DA054869 (JG), R01 AA026364 (JG), P50 AA012870 (JG), T32 AA028259 (JDD), R33 DA047527 (RP), R21 DC018098 (RP), and F32 MH122058 (FRW); the Brain & Behavior Research Foundation (HZ; DFL); and by funding from the Department of Veterans Affairs Office of Research and Development grants I01CX001849, I01BX003342, I01BX004820, IK2BX005058, and I01 CX001734, the VA Cooperative Studies Program study, no. 575B, and the VISN4 Mental Illness Research, Education and Clinical Center, and the West Haven VA Mental Illness Research, Education and Clinical Center. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.

Disclosures: HRK is a member of scientific advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sophrosyne Pharmaceuticals; a recipient of research funding and medication supplies from Alkermes for an investigator-initiated study; and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG hold U.S. patent US10900082B2: "Genotype-guided dosing of opioid agonists." RP and JG are paid for their editorial work on the journal Complex Psychiatry. All other authors report no biomedical financial interests or potential conflicts of interest.

References

1. Deak JD, Miller AP, Gizer IR. Genetics of alcohol use disorder: a review. *Current Opinion in Psychology*. 2019;27:56-61. doi:10.1016/j.copsyc.2018.07.012.

2. Gelernter J, Polimanti R. Genetics of substance use disorders in the era of big data. *Nature Reviews Genetics*. 2021;22(11):712-29. doi: 10.1038/s41576-021-00377-1.

3. Kranzler HR, Zhou H, Kember RL, et al.. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. *Nature Communications*. 2019;10(1). doi:10.1038/s41467-019-09480-8.

4. Zhou H, Sealock JM, Sanchez-Roige S, et al.. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. *Nature Neuroscience*. 2020;23(7):809-818. doi:10.1038/s41593-020-0643-5.

5. Sanchez-Roige S, Palmer AA, Fontanillas P, et al.. Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *American Journal of Psychiatry*. 2019;176(2):107-118. doi:10.1176/appi.ajp.2018.18040369.

6. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nature Genetics*. 2019;51(2):237-244. doi:10.1038/s41588-018-0307-5.

7. Mallard TT, Savage JE, Johnson EC, et al.. Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts. *American Journal of Psychiatry*. 2022;179(1):58-70. doi:10.1176/appi.ajp.2020.20091390.

8. Gelernter J, Sun N, Polimanti R, et al. Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans Yields Novel Risk Loci. *Biological Psychiatry*. 2019;86(5):365-376. doi:10.1016/j.biopsych.2019.03.984.

9. Rutledge PC, Park A, Sher KJ. 21st birthday drinking: Extremely extreme. *Journal of Consulting and Clinical Psychology*. 2008;76(3):511-516. doi:10.1037/0022-006x.76.3.511.

10. Edenberg HJ. How Much Do You Drink on Your Heavy Drinking Day?. *Biological Psychiatry*. 2019;86(5):330-332. doi:10.1016/j.biopsych.2019.06.019.

11. National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA Council Approves D efinition of Binge Drinking. NIAAA Newsletter, No. 3, Winter 2004. Available at: https://pubs.niaaa.nih.gov/publications/Newsletter/winter2004/Newsletter_Number3.pdf Accessed 4/20/22.

12. Purcell S, Neale B, Todd-Brown K, et al.. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *The American Journal of Human Genetics*. 2007;81(3):559-575. doi:10.1086/519795.

13. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190-2191. doi:10.1093/bioinformatics/btq340.

14. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393.

15. Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nature Communications*. 2017;8(1). doi:10.1038/s41467-017-01261-5.

16. Bulik-Sullivan BK, Loh P-R, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics*. 2015;47(3):291-295. doi:10.1038/ng.3211.

17. Luo Y, Li X, Wang X, et al., Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations. *Human Molecular Genetics*. 2021. doi:10.1093/hmg/ddab130.

18. Levey DF, Gelernter J, Polimanti R, et al. Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program. *American Journal of Psychiatry*. 2020;177(3):223-232. doi:10.1176/appi.ajp.2019.19030256.

19. Levey DF, Stein MB, Wendt FR, et al.. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience. 2021;24(7):954-963. doi:10.1038/s41593-021-00860-2.

20. Stein MB, Levey DF, Cheng Z, et al.. Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program. *Nature Genetics*. 2021;53(2):174-184. doi:10.1038/s41588-020-00767-x.

21. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nature Genetics*. 2018;50(3):381-389. doi:10.1038/s41588-018-0059-2.

22. Mullins N, Kang J, Campos AI, et al. Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. *Biological Psychiatry*. 2022;91(3):313-327. doi:10.1016/j.biopsych.2021.05.029.

23. Grotzinger AD, Rhemtulla M, De Vlaming R, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nature Human Behaviour*. 2019;3(5):513-525. doi:10.1038/s41562-019-0566-x.

24. Pazoki R, Vujkovic M, Elliott J, et al. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. *Nature Communications*. 2021;12(1). doi:10.1038/s41467-021-22338-2.

25. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genetics*. 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081.

26. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature Genetics*. 2018;50(5):693-698. doi:10.1038/s41588-018-0099-7.

27. Zhao Q, Wang J, Hemani G, Bowden J, Small D. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *Ann. Statist*. 2020;48(3)1742-1769. https://doi.org/10.1214/19-AOS1866

28. Turley P, Walters RK, Maghzian O, et al.. Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nature Genetics*. 2018;50(2):229-237. doi:10.1038/s41588-017-0009-4.

29. Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. *Molecular Psychiatry*. 2014;19(1):41-49. doi:10.1038/mp.2013.145.

30. Edenberg HJ, Mcclintick JN. Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders: A Critical Review. *Alcoholism: Clinical and Experimental Research*. 2018;42(12):2281-2297. doi:10.1111/acer.13904.

31. Thomasson HR, Edenberg HJ, Crabb DW, et al. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. *Am J Hum Genet*. 1991;48(4):677-681.

32. Zhong VW, Kuang A, Danning RD, et al.. A genome-wide association study of bitter and sweet beverage consumption. *Human Molecular Genetics*. 2019;28(14):2449-2457. doi:10.1093/hmg/ddz061.

33. Lanier S, Hayes J, Duffy V. Sweet and bitter tastes of alcoholic beverages mediate alcohol intake in of-age undergraduates. *Physiology & Behavior*. 2005;83(5):821-831. doi:10.1016/j.physbeh.2004.10.004.

34. Ong J-S, Hwang L-D, Zhong VW, et al. Understanding the role of bitter taste perception in coffee, tea and alcohol consumption through Mendelian randomization. *Scientific Reports*. 2018;8(1). doi:10.1038/s41598-018-34713-z.

35. Hennet T. The galactosyltransferase family. *Cellular and Molecular Life Sciences*. 2002;59(7):1081-1095. doi:10.1007/s00018-002-8489-4.

36. Waszkiewicz N, Sławomir, Kępka A, Szulc A, Zwierz K. Glycoconjugates in the detection of alcohol abuse. *Biochemical Society Transactions*. 2011;39(1):365-369. doi:10.1042/bst0390365.

37. Borges G, Bagge CL, Cherpitel CJ, Conner KR, Orozco R, Rossow I. A meta-analysis of acute use of alcohol and the risk of suicide attempt. *Psychological Medicine*. 2017;47(5):949-957. doi:10.1017/s0033291716002841.

38. Edwards AC, Sundquist K, Sundquist J, Kendler KS, Larsson Lönn S. Genetic and environmental influences on the progression from alcohol use disorder to alcohol□related

medical conditions. *Alcoholism: Clinical and Experimental Research*. 2021;45(12):2528-2535. doi:10.1111/acer.14731.

39. Boccuto L, Abenavoli L. Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. *Ann Hepatol*. 2017;16(4):490-500.

40. Whitfield J.B. Gamma Glutamyl Transferase. *Critical Reviews in Clinical Laboratory Sciences*. 2001;38(4):263-355, doi: 10.1080/20014091084227

41. Xue A, Jiang L, Zhu Z, et al. Genome-wide analyses of behavioural traits are subject to bias by misreports and longitudinal changes. *Nature Communications*. 2021;12(1). doi:10.1038/s41467-020-20237-6.

42. Kember RL, Vickers-Smith R, Zhou H, et al.. Genetic underpinnings of the transition from alcohol consumption to alcohol use disorder: shared and unique genetic architectures in a cross-ancestry sample. 2021. doi:10.1101/2021.09.08.21263302.

Table 1. GWS MaxAlc loci in the (A) cross-ancestry GWAS; (B) EUR GWAS, (C) AFR GWAS, and (D) MaxAlc MTAG GWAS.

A. Cross-ancestry MaxAlc GWS ($p \leq 5.00E\text{-}08$) lead SNPs

Chr	Position	MarkerName	A1	A2	Nearest Gene	Direction	P-value	nSNPs	nGWASSNPs	nIndSigSNPs	nLeadSNPs
4	100239319	rs1229984	C	T	*ADH1B*	-?	2.46E-101	529	393	22	9
4	103188709	rs13107325	T	C	*SLC39A8*	--	9.40E-15	23	23	4	1
17	44305199	rs570285046	C	T	*CRHR1*	++	2.12E-14	3590	3538	29	3
7	135162897	rs2551763	T	C	*CNOT4*	-?	1.29E-09	29	18	1	1
9	30359634	rs13297433	A	G	*snoU13*	++	2.01E-09	76	73	2	1
11	47392114	rs7928419	A	G	*SPI1*	++	2.29E-09	196	172	3	1
1	7830262	rs2153733	C	T	*CAMTA1*	+?	1.36E-08	1	1	1	1
19	37504953	rs826323	A	G	*ZNF420*	++	1.39E-08	162	153	1	1
9	33094361	rs56175925	A	G	*B4GALT1*	?+	1.82E-08	5	5	1	1
10	10704659	rs34165302	C	CA	*RP1-186E20.1*	-?	2.08E-08	87	35	1	1
10	110572259	rs1577857	G	T	*RP11-655H13.2*	+?	2.47E-08	100	82	1	1
2	104056769	rs6752675	A	G	*AC092568.1*	--	2.57E-08	196	170	1	1
2	27730940	rs1260326	C	T	*GCKR*	--	2.63E-08	9	9	1	1
11	113392994	rs2514218	T	C	*DRD2*	--	4.59E-08	25	23	1	1

B. EUR MaxAlc GWS (p≤5.00E-08) Lead SNPs

Chr	Position	MarkerName	A1	A2	Nearest Gene	MAF	P-value	nSNPs	nGWASSNPs	nIndSigSNPs	nLeadSNPs
4	100239319	rs1229984	C	T	*ADH1B*	0.04	3.12E-101	420	275	14	8
4	103188709	rs13107325	T	C	*SLC39A8*	0.08	6.78E-15	24	24	2	1
17	43810896	rs77804065	T	C	*CRHR1*	0.23	6.04E-14	3839	3533	4	2
11	47676170	rs7107356	G	A	*AGBL2*	0.5	1.43E-10	422	313	3	1
7	135162897	rs2551763	T	C	*CNOT4*	0.41	1.30E-09	43	19	1	1
1	7830262	rs2153733	C	T	*CAMTA1*	0.19	1.36E-08	35	31	1	1
10	10714452	rs145961009	C	CTT	*RP1-186E20.1*	0.22	1.73E-08	133	42	1	1
9	30346448	rs4879424	C	T	*snoU13*	0.15	2.18E-08	190	169	1	1
10	110572259	rs1577857	G	T	*RP11-655H13.2*	0.26	2.47E-08	122	102	1	1
2	27730940	rs1260326	C	T	*GCKR*	0.42	4.53E-08	18	18	1	1

C. AFR MaxAlc GWS (p≤5.00E-08) Lead SNPs

Chr	Position	MarkerName	A1	A2	Nearest Gene	MAF	P-value	nSNPs	nGWASSNPs	nIndSigSNPs	nLeadSNPs
4	100229017	rs2066702	A	G	*ADH1B*	0.19	6.30E-17	109	103	7	1
9	33094361	rs56175925	A	G	*B4GALT1*	0.02	1.83E-08	6	5	1	1

D. MaxAlc MTAG GWS (p≤5.00E-08) Lead SNPs

Chr	Position	MarkerName	A1	A2	Nearest Gene	MAF	P-value	nSNPs	nGWASSNPs	nIndSigSNPs	nLeadSNPs
4	100239319	rs1229984	T	C	*ADH1B*	0.04	3.35E-176	1291	646	26	9
4	103188709	rs13107325	T	C	*SLC39A8*	0.08	6.01E-36	75	26	6	1
2	27730940	rs1260326	T	C	*GCKR*	0.41	2.72E-21	261	98	4	1
4	39423789	rs4975013	A	G	*KLB*	0.39	1.44E-19	64	27	4	1
11	113364691	rs17602038	T	C	*DRD2*	0.37	2.62E-16	70	36	3	2
11	47406592	rs11039216	T	C	*RP11-750H9.5*	0.47	1.07E-15	519	245	5	1
17	44083402	rs1991556	A	G	*MAPT*	0.23	2.25E-15	3854	2089	2	1
10	110572259	rs1577857	T	G	*RP11-655H13.2*	0.26	6.44E-15	494	304	2	1
2	104361420	rs9308868	A	G	*AC013727.1*	0.49	4.88E-13	518	329	3	1
14	58765903	rs61974485	T	C	*ARID4A*	0.28	1.02E-12	117	5	1	1
2	45139904	rs472140	T	C	*RP11-89K21.1*	0.42	1.11E-11	50	5	2	1
7	135119417	rs2551774	A	G	*CNOT4*	0.41	1.50E-11	43	14	1	1
10	10688361	rs7910201	A	G	*RP1-186E20.1*	0.25	6.36E-11	168	69	2	1
16	53834607	rs7188250	T	C	*FTO*	0.41	8.06E-10	106	82	1	1
7	153487944	rs2098112	A	G	*DPP6*	0.47	8.99E-10	112	2	1	1
19	49244219	rs2307018	A	C	*IZUMO1*	0.43	9.98E-10	59	21	1	1
1	66503517	rs1354063	T	C	*PDE4B*	0.47	1.21E-09	224	81	3	1
15	47681384	rs8033799	A	C	*CTD-2050N2.1*	0.21	1.86E-09	157	65	2	1
5	153364650	rs2245405	A	G	*FAM114A2*	0.45	2.24E-09	70	32	1	1
22	41789408	rs4822028	A	G	*TEF*	0.23	7.97E-09	762	503	2	2
12	81602449	rs1921035	A	G	*ACSS3*	0.48	8.44E-09	100	55	1	1
2	144225215	rs13024996	A	C	*RP11-570L15.2*	0.36	8.56E-09	29	7	1	1
13	97019647	rs1925104	T	G	*HS6ST3*	0.33	1.37E-08	100	56	1	1
8	21831385	rs1484162	A	G	*XPO7*	0.41	1.49E-08	56	15	1	1
2	138197269	rs10496771	T	C	*THSD7B*	0.25	1.56E-08	222	84	1	1
20	18546199	rs6045466	T	C	*LINC00493*	0.47	1.92E-08	150	102	1	1
2	58042241	rs1402398	A	G	*CTD-2026C7.1*	0.39	2.00E-08	268	55	2	1
7	117576675	rs6466637	A	G	*AC007568.1*	0.28	2.00E-08	39	22	1	1
7	73015369	rs13240065	A	G	*MLXIPL*	0.12	2.95E-08	66	46	1	1
2	204123832	rs56059523	T	C	*CYP20A1*	0.11	3.17E-08	18	5	1	1
3	18793340	rs9835977	T	C	*AC144521.1*	0.30	3.57E-08	79	44	1	1

Table 2. MVP MaxAlc loci summary table.

Position	MaxAlc II GWS	Ancestry	Nearest Gene	Novel locus	MaxAlc I GWS	Alcohol Use	PAU	AUDIT-P	AUDIT-C	DPW	Locus previously GWS for other related outcomes
4:100239319	rs1229984	EUR	*ADH1B*		+	+	+	+	+	+	
4:100229017	rs2066702	AFR	*ADH1B*		+	+					
4:103188709	rs13107325	EUR	*SLC39A8*			+	+	+	+	+	Sleep, Schizophrenia
17:43810896	rs77804065	EUR	*CRHR1*		+					+	Neuroticism, Feeling Guilty
11:47676170	rs7107356	EUR	*AGBL2*	+							Neuroticism, Well-being, Prefers bitter alcohol beverage
7:135162897	rs2551763	EUR	*CNOT4*	+							Educational attainment
1:7830262	rs2153733	EUR	*CAMTA1*	+							Morningness
19: 37504953	rs826323	CROSS	*ZNF420*	+							Body shape, Body mass index
10:10714452	rs145961009	EUR	*RP1-186E20.1*	+							
9:33094361	rs56175925	AFR	*B4GALT1*	+							Aspartate aminotransferase levels
9:30346448	rs4879424	EUR	*snoU13*	+							
10:110572259	rs1577857	EUR	*RP11-655H13.2*		+		+				
2:104056769	rs6752675	CROSS	*AC092568.1*	+							
2:27730940	rs1260326	EUR	*GCKR*			+	+		+	+	
11:113392994	rs2514218	CROSS	*DRD2*			+	+				Depression, Neuroticism, Well-being

Note: Genome-wide significant (GWS; 5.0×10^{-08}). Abbreviations (left to right): Maximum habitual alcohol intake (MaxAlc); Problematic alcohol use (PAU); Alcohol use disorders identification test – problems (AUDIT-P); Alcohol use disorders identification test – consumption (AUDIT-C); Drinks per week (DPW).

Figure 1. Manhattan plot of MaxAlc GWAS in 247,755 individuals of African (AFR) and European (EUR) ancestry.

Note: Red-dashed line indicates genome-wide significance (GWS; 5.00x10⁻⁰⁸). Low panel: Blue circle indicates GWS in AFR; Red circle indicates GWS in EUR; Green circle indicates GWS in the cross-ancestry meta-analysis.

Figure 2. Genetic correlations between MVP MaxAlc, alcohol traits, and psychiatric outcomes.

Note: Abbreviations (along diagonal): Maximum habitual alcohol intake (MaxAlc); Problematic alcohol use (PAU); Alcohol use disorder (AUD); Alcohol Use Disorders Identification Test-Problems (AUDIT-P); Drinks per week (DPW); AUDIT-Total (AUDIT-T); AUDIT-Consumption (AUDIT-C); ICD-based Depression (ICDdepMVP); PTSD Checklist -Total score (PCL_Total); Generalized Anxiety Disorder 2-item (GAD-2).

Figure 3. Genomic-SEM of MVP MaxAlc and other alcohol use traits.

Note: Abbreviations (left to right): Maximum habitual alcohol intake (MaxAlc); Alcohol use disorder (AUD); Problematic alcohol use (PAU); Alcohol Use Disorders Identification Test-Problems (AUDIT-P); Drinks per week (DPW); AUDIT-Consumption (AUDIT-C). We interpret Factor 1 to capture "alcohol use problems" and Factor 2 to capture "non-dependent alcohol consumption."